The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors.
Belani
Chandra P
CP
Penn State Hershey Cancer Institute, Penn State Milton S. Hershey Medical Center, 500 University Drive, Hershey, PA 17033, USA. cbelani@psu.edu
D000077716:Afatinib; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D009025:Morpholines / Q000627:therapeutic use; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use; D052999:Quinazolinones / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use
D009025:Morpholines; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D052999:Quinazolinones; D011804:Quinolines; D000077716:Afatinib; C525726:dacomitinib; C420268:Canertinib; D066246:ErbB Receptors; C487932:neratinib